Nanoliposome-based antibacterial drug delivery

Drug Delivery

Volumn 22, Issue 5, 2015, Pages 581-589

  Hallaj Nezhadi, Somayeh ^a   Hassan, Maryam ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antibiotic; Antimicrobial agents; Drug delivery; Liposome; Nanoparticle

Indexed keywords

ANTIBIOTIC AGENT; LIPOSOME; NANOCARRIER; NANOPARTICLE; ANTIINFECTIVE AGENT; DRUG CARRIER;

ANTIBACTERIAL ACTIVITY; BACTERIAL CELL; BACTERIAL INFECTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; FUTUROLOGY; HOST; HUMAN; LIPOSOMAL DELIVERY; NANOMEDICINE; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOPARTICLES;

EID: 84937894017     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.863409     Document Type: Review

References (45)

1. Alexis F, Pridgen EM, Langer R, Farokhzad OC. (2010). Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol 197:55-86.
2. Bakker-Woudenberg IA, Lokerse AF. (1990). Liposomes and lipid carriers in the treatment of microbial infections. Scand J Infect Dis Suppl 74:34-41.
3. Barzegar-Jalali M, Adibkia K, Valizadeh H, et al. (2008). Kinetic analysis of drug release from nanoparticles. J Pharm Pharm Sci 11: 167-77.
4. Changsan N, Chan HK, Separovic F, Srichana T. (2009). Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J Pharm Sci 98:628-39.
5. Clardy J, Fischbach M, Currie C. (2009). The natural history of antibiotics. Curr Biol 19:R437-41.
6. Coune A. (1988). Liposomes as drug delivery system in the treatment of infectious diseases. Potential applications and clinical experience. Infection 16:141-7.
7. De Leeuw J, De Vijlder HC, Bjerring P, Neumann HA. (2009). Liposomes in dermatology today. J Eur Acad Dermatol Venereol 23: 505-16.
8. Drulis-Kawa Z, Dorotkiewicz-Jach A, Gubernator J, et al. (2009). The interaction between Pseudomonas aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell. Int J Pharm 367:211-9.
9. Drulis-Kawa Z, Gubernator J, Dorotkiewicz-Jach A, et al. (2006). In vitro antimicrobial activity of liposomal meropenem against Pseudomonas aeruginosa strains. Int J Pharm 315:59-66.
10. Faraji AH, Wipf P. (2009). Nanoparticles in cellular drug delivery. Bioorg Med Chem 17:2950-62.
11. Fresta M, Spadaro A, Cerniglia G, et al. (1995). Intracellular accumulation of ofloxacin-loaded liposomes in human synovial fibroblasts. Antimicrob Agents Chemother 39:1372-5.
12. Gharib A, Faezizadeh Z, Godarzee M. (2012a). In vitro and in vivo activities of ticarcillin-loaded nanoliposomes with different surface charges against Pseudomonas aeruginosa (ATCC 29248). DARU J Pharm Sci 20:41.
13. Gharib A, Faezizadeh Z, Godarzee M. (2012b). Therapeutic efficacy of epigallocatechin gallate-loaded nanoliposomes against burn wound infection by methicillin-resistant Staphylococcus aureus. Skin Pharmacol Physiol 26:68-75.
14. Goyal P, Goyal K, Vijaya Kumar SG, et al. (2005). Liposomal drug delivery systems: clinical applications. Acta Pharm 55:1-25.
15. Hallaj-Nezhadi S, Dass CR, Lotfipour F. (2013a). Intraperitoneal delivery of nanoparticles for cancer gene therapy. Future Oncol 9: 59-68.
16. Hallaj-Nezhadi S, Lotfipour F, Dass C. (2010). Nanoparticle-mediated interleukin-12 cancer gene therapy. J Pharm Pharm Sci 13:472-85.
17. Hallaj-Nezhadi S, Valizadeh H, Baradaran B, et al. (2013b). Preparation and characterization of gelatin nanoparticles containing pDNA encoding IL-12 and their expression in CT-26 carcinoma cells. Future Oncol 9:1195-206.
18. Halwani M, Mugabe C, Azghani AO, et al. (2007). Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. J Antimicrob Chemother 60:760-9.
19. Halwani M, Yebio B, Suntres ZE, et al. (2008). Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J Antimicrob Chemother 62:1291-7.
20. Hassan M, Diep DB, Javadzadeh Y, et al. (2012a). Prevalence of bacteriocin activities and bacteriocin-encoding genes in enterococcal clinical isolates in Iran. Can J Microbiol 58:359-68.
21. Hassan M, Kjos M, Nes IF, et al. (2012b). Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance. J Appl Microbiol 113:723-36.
22. Huang CM, Chen CH, Pornpattananangkul D, et al. (2011). Eradication of drug resistant Staphylococcus aureus by liposomal oleic acids. Biomaterials 32:214-21.
23. Immordino ML, Dosio F, Cattel L. (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 1:297.
24. Ishida T, Harashima H, Kiwada H. (2002). Liposome clearance. Biosci Rep 22:197-224.
25. Li C, Zhang X, Huang X, et al. (2013). Preparation and characterization of flexible nanoliposomes loaded with daptomycin, a novel antibiotic, for topical skin therapy. Int J Nanomedicine 8:1285-92.
26. Ma Y, Wang Z, Zhao W, et al. (2013). Enhanced bactericidal potency of nanoliposomes by modification of the fusion activity between liposomes and bacterium. Int J Nanomedicine 8:2351-60.
27. Maurer N, Fenske DB, Cullis PR. (2001). Developments in liposomal drug delivery systems. Expert Opin Biol Ther 1:923-47.
28. Mugabe C, Azghani AO, Omri A. (2005). Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 55:269-71.
29. Mugabe C, Azghani AO, Omri A. (2006a). Preparation and characterization of dehydration-rehydration vesicles loaded with aminoglycoside and macrolide antibiotics. Int J Pharm 307:244-50.
30. Mugabe C, Halwani M, Azghani AO, et al. (2006b). Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:2016-22.
31. Muller RH, Keck CM. (2004). Challenges and solutions for the delivery of biotech drugs: a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 113:151-70.
32. Nahaei M, Valizadeh H, Baradaran B, et al. (2013). Preparation and characterization of chitosan/beta-cyclodextrin nanoparticles containing plasmid DNA encoding interleukin-12. Drug Res (Stuttg) 63:7-12.
33. Obonyo M, Zhang L, Thamphiwatana S, et al. (2012). Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori. Mol Pharm 9:2677-85.
34. Pierre MB, Dos Santos Miranda Costa I. (2011). Liposomal systems as drug delivery vehicles for dermal and transdermal applications. Arch Dermatol Res 303:607-21.
35. Pinheiro M, Lúcio M, Lima JL, Reis S. (2011). Liposomes as drug delivery systems for the treatment of TB. Nanomedicine 6: 1413-28.
36. Pinto-Alphandary H, Andremont A, Couvreur P. (2000). Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int J Antimicrob Agents 13:155-68.
37. Puglia C, Bonina F. (2012). Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin Drug Deliv 9:429-41.
38. Rahimpour Y, Hamishehkar H. (2012). Liposomes in cosmeceutics. Expert Opin Drug Deliv 9:443-55.
39. Rukholm G, Mugabe C, Azghani AO, Omri A. (2006). Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study. Int J Antimicrob Agents 27:247-52.
40. Sachetelli S, Khalil H, Chen T, et al. (2000). Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim Biophys Acta 1463:254-66.
41. Swenson CE, Popescu MC, Ginsberg RS. (1988). Preparation and use of liposomes in the treatment of microbial infections. Crit Rev Microbiol 15:S1-31.
42. Thamphiwatna S, Fu V, Zhu J, et al. (2013). Nanoparticle-stabilized liposomes for pH-responsive gastric drug delivery. Langmuir 29: 12228-33.
43. Toh M-R, Chiu GN. (2013). Liposomes as sterile preparations and limitations of sterilisation techniques in liposomal manufacturing. Asian J Pharm Sci 8:88-95.
44. Vasir JK, Reddy MK, Labhasetwar VD. (2005). Nanosystems in drug targeting: opportunities and challenges. Curr Nanosci 1:47-64.
45. Yang D, Pornpattananangkul D, Nakatsuji T, et al. (2009). The antimicrobial activity of liposomal lauric acids against Propionibacterium acnes. Biomaterials 30:6035-40.